Platinum-based chemotherapy in metastatic breast cancer: current status.
作者： M.P Decatris , S Sundar , K.J O’Byrne
DOI: 10.1016/S0305-7372(03)00139-7
关键词: Carboplatin 、 Metastatic breast cancer 、 Oxaliplatin 、 Cisplatin 、 Docetaxel 、 Breast cancer 、 Internal medicine 、 Medicine 、 Gemcitabine 、 Oncology 、 Trastuzumab
摘要: Cisplatin and carboplatin are active in previously untreated patients with metastatic breast cancer (MBC) mean response rates (RRs) of 50 32%, respectively. In pretreated the RR to cisplatin/carboplatin monotherapy declines markedly 80%). This would suggest that chemotherapy-naive platinum-based therapy might have an important role play. Additionally synergy demonstrated between platinum compounds, taxanes herceptin, preclinical clinical studies is immense importance results two ongoing Breast Cancer International Research Group randomized phase III eagerly awaited. These may help clarify compounds treatment possibly early cancer.
mysciencework.com
elsevier.com参考文章(246)
B. J. M. Braakhuis, G. J. Peters, C. M. Kuiper, G. Veerman, V. W. T. Ruiz Van Haperen, A. M. Bergman, Interaction between cisplatin and gemcitabine in vitro and in vivo. Seminars in Oncology. ,vol. 22, pp. 72- 79 ,(1995)
Stewart Dj, Tetreault L, Maroun Ja, Nundy D, Prior J, Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. Cancer treatment reports. ,vol. 69, pp. 269- 273 ,(1985)
James N. Ingle, Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. Oncology. ,vol. 15, pp. 28- 34 ,(2001)
Alexopoulos C, Subramarian S, Barker Gh, Wiltshaw E, Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital. Cancer treatment reports. ,vol. 63, pp. 1545- ,(1979)
Krsto Kolarić, Dunja Vukas, Vera Potrebica, Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. Tumori. ,vol. 75, pp. 132- 136 ,(1989) , 10.1177/030089168907500210
M Boisdron-Celle, E Gamelin, [Pharmacology of platinum analogs-taxanes interactions]. Bulletin Du Cancer. pp. 30- 33 ,(2000)
K. J. Scanlon, Y. Lu, M. Kashani-Sabet, J. x. Ma, E. Newman, Mechanisms for Cisplatin-FUra Synergism and Cisplatin Resistance in Human Ovarian Carcinoma Cells both in vitro and in vivo Advances in Experimental Medicine and Biology. ,vol. 244, pp. 127- 135 ,(1988) , 10.1007/978-1-4684-5607-3_12
Krsto Kolarić, Dunja Vukas, Anton Roth, Vera Potrebica, Jožica Cervek, O. Cerar, Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report. Tumori. ,vol. 71, pp. 159- 165 ,(1985) , 10.1177/030089168507100212
M D Pegram, R J Pietras, S B Howell, V R Chazin, B M Fendly, D J Slamon, Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. ,vol. 9, pp. 1829- 1838 ,(1994)
G. J. Forrest, D. Cunningham, M. Soukop, Lesley McTaggart, J. F. B. Stuart, J. Cummings, Etoposide: a pharmacokinetic profile including an assessment of bioavailability. Medical oncology and tumor pharmacotherapy. ,vol. 3, pp. 95- 99 ,(1986) , 10.1007/BF02934560